Crossroads Podiatry & Ingrown Newnan, GA - 30265

Crossroads Podiatry & Ingrown is categorized under Podiatrists in Newnan, GA and active since 1995.

Crossroads Podiatry & Ingrown was established in 1995, and today employs 1 to 4, earning $500.000 to $999.999 per year. This is a Podiatrists business, which does work in the B2C market, and is classified as a Podiatrists, under code number 6213910 by the NAICS.

If you are seeking more information, feel free to contact Everett Mason III, Owner at the company’s single location by writing to 3231 Highway 34 East # C, Newnan, Georgia GA 30265 or by phoning (770) 251-8940. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Crossroads Podiatry & Ingrown
Contact Person: Everett Mason III, Owner
Address: 3231 Highway 34 East # C, Newnan, Georgia 30265
Phone Number: (770) 251-8940
Website Address: accesspodiatrist.com
Annual Revenue (USD): $500.000 to $999.999
Founded: 1995
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2C (Business to Consumer)
Business Category: Podiatrists
SIC Code: 8043
NAICS Code: 6213910
Share This Business:

Crossroads Podiatry & Ingrown was started in 1995 to provide professional Podiatrists under the SIC code 8043 and NAICS code 6213910. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $500.000 to $999.999 per annum.

Feel free to contact Everett Mason III, Owner for inquiries that concern Crossroads Podiatry & Ingrown by calling the company number (770) 251-8940, as your correspondence is most welcome. Additionally, the physical location of the single location of Crossroads Podiatry & Ingrown can be found at the coordinates 33.40738,-84.67754 as well as the street address 3231 Highway 34 East # C in Newnan, Georgia 30265.

For its online presence, you may visit Crossroads Podiatry & Ingrown’s website at accesspodiatrist.com and engage with its social media outlets through on Twitter and on Facebook.